Servier Bio-innovation Llc

This early-stage study aimed to test the safety and initial effectiveness of a three-drug combination for people with advanced bile duct cancer that has a specific genetic change (IDH1 mutation). The treatment combined a targeted drug (ivosidenib) with two immunotherapy drugs. Th…

This study tested a new drug called S227928, both by itself and combined with an existing drug (venetoclax), for people with advanced forms of leukemia and related blood cancers that had stopped responding to standard treatments. The main goals were to find a safe and effective d…